Document is current

Article History

Received: 1 March 2022

Revised: 2 June 2022

Accepted: 28 June 2022

First Online: 22 July 2022

Competing interests

: MD received research funding from AstraZeneca and Merck, and speaking honoraria from AstraZeneca, Roche, Merck, Boehringer Ingelheim, Eisai and Takeda. VT received research funding from AstraZeneca, Eisai, Exelixis, Ipsen, Merck, Roche, travel support from Amgen, and speaking honoraria from AstraZeneca, Eisai, Ipsen and Roche. MM received research support from Servier, Ipsen, and NuCana, travel/accommodation support from Bayer and Ipsen, speaker honoraria from Pfizer, Ipsen, NuCana, and Mylan, and consulted for Celgene, Ipsen, Sirtex, Baxalta and Incyte. RJ received research funding from AstraZeneca, Boston Biomedical, Bristol-Myers Squibb, Lilly, Merck and Novartis, and consulted for Ipsen and Novartis. EC received research funding from AstraZeneca, Boston Biomedical, Bristol-Myers Squibb, Merck and Novartis, and speaking honoraria from Bayer, Eisai and Taiho. ND received speaker honoraria from Celgene and Sanofi, and consulted for Celgene and Incyte. PT received travel support from Amgen and consulted for Amgen, AstraZeneca, Celgene, Eisai, Genomic Health International, Merck, Pfizer, Taiho and Teva. HWS received research funding from Abbvie and Bristol-Meiers Squibb. GO’K received speaking honoraria from Eisai and Roche, travel support from AstraZeneca, and consulted for Eisai and Roche. JK received research funding from and consulted for AstraZeneca, Ipsen and Merck, and speaking honoraria from Novartis and Roche. The remaining authors declare no competing interests.

: This study was approved by the Research Ethics Boards of the Princess Margaret Cancer Centre and Tom Baker Cancer Centre. All patients provided informed consent and the study was carried out in accordance with the Declaration of Helsinki. The trial was registered with clinicaltrials.gov, ID NCT02151084.

: None.